FierceBiotech

Novo Nordisk Licenses IL-21 mAb and Patent Rights to IL-21 Antibodies from ZymoGenetics

24 Million US Dollars Upfront Payment with 157.5 Million Dollars of Total Potential Milestone Payments SEATTLE & COPENHAGEN, Dec 08, 2009 (BUSINESS WIRE) -- Novo Nordisk A/S (NYSE:NVO) and ...
PharmiWeb

Asher Bio to Unveil Two New Immunotherapy Programs, a CD8+ T Cell Targeted IL-21 and a Cis-Targeted IL-2 for Cell Therapy Augmentation, at AACR Annual Meeting

– New preclinical data support advancement of AB821 as a CD8+ T cell targeted IL-21; investigational new drug (IND) application filing expected 2H 2023 – – New preclinical data provide foundational ...
News Medical

Novo Nordisk in-licenses intellectual property rights to IL-21 antibodies

Novo Nordisk A/S (NYSE:NVO) and ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced an agreement where Novo Nordisk in-licenses a fully-human anti-IL21 monoclonal antibody (IL-21 mAb) developed by ...
BioWorld

ZymoGenetics Narrows Focus Again; Licenses Anti-IL21 mAb

ZymoGenetics Inc. continued its transformation from a discovery engine to a development and sales organization, this time out-licensing its preclinical anti-IL21 antibody to former parent company Novo ...
Nature

Generation of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer

T-cell receptor (TCR) gene transfer is an attractive strategy to generate antigen-specific T-cells for adoptive immunotherapy of cancer and chronic viral infection. However, current TCR gene transfer ...
Pharmabiz

Asher Bio to unveil two new immunotherapy programmes, a CD8+ T cell targeted IL-21 & cis-targeted IL-2 for cell therapy augmentation, at AACR meeting

In the MC38 tumor model, for example, treatment with a single dose of CD8-IL21 as low as 0.1 mg/kg induced complete regression of established tumors without toxicity and, in cynomolgus monkeys, ...